METACARE CO., Ltd. (KRX:118000)
South Korea · Delayed Price · Currency is KRW 1,413.00
-19.00 (-1.33%)
Last updated: Aug 12, 2026, 2:11 PM KST
METACARE CO. Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 36,948 | 32,822 | 20,208 | 17,257 | 19,098 | 18,613 |
Revenue Growth | 73.34% | 62.42% | 17.10% | -9.64% | 2.61% | 181.12% |
Gross Profit Gross Profit Growth | 10,708 | 9,968 | 7,644 | 6,499 | 6,486 | 5,063 |
Operating Income Operating Income Growth | 1,368 | 1,325 | 1,505 | 1,003 | -240.47 | -1,786 |
Net Income Net Income Growth | 923.61 | 498.24 | 8,497 | -14,540 | -49,555 | 7,740 |
Earnings Per Share EPS Growth | 54.25 | 29.57 | 561.53 | -1380.00 | -5910.00 | 1001.28 |
EPS Growth | - | -94.73% | - | - | - | -61.85% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Medical Services Consulting Division Medical Services Consulting Division Growth | - | 9,931 | - | - | - | - |
Real Estate Business Division Real Estate Business Division Growth | 3,494 | 3,601 | 558.56 | - | - | - |
Medical Division Medical Division Growth | 3,987 | 4,227 | 4,040 | 3,276 | 2,927 | 1,853 |
Pharmaceutical Sector Pharmaceutical Sector Growth | 14,717 | 15,063 | 15,610 | 13,980 | 16,171 | 16,733 |
Total Total Growth | 36,948 | 32,822 | 20,208 | 17,257 | 19,098 | 18,613 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,781 | 1,820 | 30,116 | 22,401 | 29,740 | 59,236 |
Total Debt Total Debt Growth | 52,393 | 59,322 | 35,572 | 3,354 | 35,041 | 29,853 |
Net Cash (Debt) Net Cash Growth | -49,612 | -57,503 | -5,455 | 19,047 | -5,301 | 29,383 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -2914.16 | -3412.71 | -360.54 | 1805.24 | -631.69 | 3004.04 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 4,919 | 2,420 | 4,477 | -12,857 | -2,529 | -1,492 |
Capital Expenditures CapEx Growth | -796.03 | -25,208 | -41,853 | -535.15 | -109.28 | -26.48 |
Free Cash Flow Free Cash Flow Growth | 4,123 | -22,789 | -37,376 | -13,392 | -2,638 | -1,518 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 28.98% | 30.37% | 37.83% | 37.66% | 33.96% | 27.20% |
Operating Margin | 3.70% | 4.04% | 7.45% | 5.81% | -1.26% | -9.59% |
Pretax Margin | 1.15% | -0.62% | 9.38% | -26.33% | -259.47% | 40.28% |
Profit Margin | 2.50% | 1.52% | 42.05% | -84.26% | -259.47% | 41.58% |
FCF Margin | 11.16% | -69.43% | -184.96% | -77.61% | -13.81% | -8.16% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 26.36 | 105.15 | 5.47 | - | - | 15.81 |
PS Ratio | 0.66 | 1.60 | 2.30 | 3.31 | 2.31 | 6.58 |